- Home
- YI vs SKYE Comparison
YI vs SKYE Comparison
Compare YI & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YI
- SKYE
- Stock Information
- Founded
- YI 2010
- SKYE 2012
- Country
- YI China
- SKYE United States
- Employees
- YI N/A
- SKYE N/A
- Industry
- YI Retail-Drug Stores and Proprietary Stores
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- YI Consumer Staples
- SKYE Health Care
- Exchange
- YI Nasdaq
- SKYE Nasdaq
- Market Cap
- YI 70.0M
- SKYE 80.7M
- IPO Year
- YI N/A
- SKYE N/A
- Fundamental
- Price
- YI $8.17
- SKYE $1.98
- Analyst Decision
- YI
- SKYE Buy
- Analyst Count
- YI 0
- SKYE 6
- Target Price
- YI N/A
- SKYE $16.60
- AVG Volume (30 Days)
- YI 12.9K
- SKYE 223.6K
- Earning Date
- YI 06-10-2025
- SKYE 05-08-2025
- Dividend Yield
- YI N/A
- SKYE N/A
- EPS Growth
- YI N/A
- SKYE N/A
- EPS
- YI N/A
- SKYE N/A
- Revenue
- YI $1,973,017,082.00
- SKYE N/A
- Revenue This Year
- YI N/A
- SKYE N/A
- Revenue Next Year
- YI N/A
- SKYE N/A
- P/E Ratio
- YI N/A
- SKYE N/A
- Revenue Growth
- YI N/A
- SKYE N/A
- 52 Week Low
- YI $4.15
- SKYE $1.14
- 52 Week High
- YI $13.00
- SKYE $12.11
- Technical
- Relative Strength Index (RSI)
- YI 54.03
- SKYE 50.21
- Support Level
- YI $7.54
- SKYE $1.88
- Resistance Level
- YI $8.16
- SKYE $2.28
- Average True Range (ATR)
- YI 0.42
- SKYE 0.23
- MACD
- YI 0.04
- SKYE 0.00
- Stochastic Oscillator
- YI 79.25
- SKYE 40.00
About YI 111 Inc.
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.